Though concerned about COVID-19, cigar smokers are smoking more, survey finds
A Seller’s Market: Site budgeting in the time of COVID-19
Tool could improve success in translating drugs from animal studies to humans
Photodynamic therapy can combat secondary infections in COVID-19 patients
National Cancer Institute designates Penn’s Abramson Cancer Center as ‘exceptional’
European Heart Journal: Cell infusions benefit heart patients
Merck, Hanmi Seal Licence Deal For Fatty Liver Disease Therapy
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients
These 2 Small-Cap Stocks Could See 50%-Plus Gains, Says Canaccord
These 2 Small-Cap Stocks Could See Over 50% Gains, Says Canaccord
Eli Lilly Kicks Off Covid-19 Antibody Trial In Nursing Home Residents
Overcoming Scale-Up Challenges in Gene Therapy Manufacturing
CRISPR Startups Give Genome Editing Several New Twists
Preparing for an influx of cell and gene therapy approvals
Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab
Vaccine Hunt: Is Injecting Human Volunteers With COVID-19 Ethical?
Siemens Healthineers To Snap Up Varian Medical For $16.4 Billion
3 Monster Growth Stocks That Are Still Undervalued
Oppenheimer: These 3 "Strong Buy" Stocks Have Over 50% Upside Potential
Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failure
BMS ‘bet’ with Celgene shareholders in balance after CAR-T refile
Buy This Coronavirus Stock on Weakness, Says 5-Star Analyst
2 "Strong Buy" Healthcare Stocks That Could Be the Next M&A Target
Setback in COVID-19 effort as Roche’s Actemra fails in key trial
Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out
3 "Perfect 10" Stocks to Snap Up Now
After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything
Pitt collaborative receives $7 million for COVID-19 outpatient convalescent plasma therapy
BrainStorm's (BCLI) COVID-19 Program Could Drive More Upside, Says 5-Star Analyst